8:31 AM ET
8-K
Investor Presentation
Evommune Investor Presentation
Evommune, Inc. has filed an updated corporate presentation as an exhibit to its 8-K, providing a strategic overview of its clinical-stage portfolio including EVO756, EVO301, and EVO646. The presentation outlines the company's focus on chronic inflammatory diseases and highlights its leadership team's track record of approximately 30 approved NDAs and BLAs.